Research Article

Gut Microbiota, Microinflammation, Metabolic Profile, and Zonulin Concentration in Obese and Normal Weight Subjects

Agnieszka Żak-Gołąb, Piotr Kocelak, Małgorzata Aptekorz, Maria Zientara, Łukasz Juszczyk, Gayane Martirosian, Jerzy Chudek, and Magdalena Olszanecka-Glinianowicz

1 Pathophysiology Unit, Department of Pathophysiology, Medical University of Silesia, University of Silesia, 18 Medyków Street, 40-752 Katowice, Poland
2 Health Promotion and Obesity Management Unit, Department of Pathophysiology, Medical University of Silesia, University of Silesia, 18 Medyków Street, 40-752 Katowice, Poland
3 Department of Medical Microbiology, Medical University of Silesia, University of Silesia, 18 Medyków Street, 40-752 Katowice, Poland

Correspondence should be addressed to Piotr Kocelak; pkocelak@sum.edu.pl

Received 3 April 2013; Revised 22 May 2013; Accepted 12 June 2013

Academic Editor: Malgorzata Kotula-Balak

Copyright © 2013 Agnieszka Żak-Gołąb et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The association between gut microbiota and circulating zonulin level, a marker of intestinal permeability, has not been studied yet. The aim of the study is the assessment of plasma zonulin, haptoglobin and proinflammatory cytokines (TNF-$\alpha$ and IL-6) levels in relation to composition of gut microbiota in obese and normal weight subjects. Circulating inflammation markers, such as TNF-$\alpha$, sTNFR1, sTNFR2, IL-6, zonulin, and haptoglobin levels were measured and semiquantitative analysis of gut microbiota composition was carried out in 50 obese and 30 normal weight subjects without concomitant diseases. Higher circulating zonulin, TNF-$\alpha$, sTNFR1, sTNFR2, and IL-6 levels were found in the obese subjects. Plasma zonulin level correlated positively with age ($r = 0.43$, $P < 0.001$), body mass ($r = 0.30$, $P < 0.01$), BMI ($r = 0.33$, $P < 0.01$), fat mass and fat percentage ($r = 0.31$, $P < 0.01$ and $r = 0.23$, $P < 0.05$, resp.). Positive correlations between bacterial colony count and sTNFRI ($r = 0.33$, $P < 0.01$) and plasma zonulin ($r = 0.26$, $P < 0.05$) but not haptoglobin levels were found. Additionally, plasma zonulin level was proportional to daily energy intake ($r = 0.27$, $P < 0.05$) and serum glucose concentration ($r = 0.18$, $P < 0.05$) and inversely proportional to diet protein percentage ($r = -0.23$, $P < 0.05$). Gut microbiota-related systemic microinflammation in the obese is reflected by circulating zonulin level, a potential marker of interstitial permeability.

1. Introduction

The results of numerous studies suggested that changes in the composition of gut microbiota are factors participating in the development of obesity by obtaining extra energy from the portion of food, reduced expression of FIAF (fasting-induced adipocyte factor) in the enterocytes with inhibitory activity on intestinal lipoprotein lipase, and the increased release of peptide YY that slows the intestinal motility [1].

Obesity, especially visceral, is associated with systemic microinflammation [2–4]. Adipocytes and even more macrophages infiltrating visceral adipose tissue in obese subjects are the source of circulating proinflammatory cytokines, such as TNF-$\alpha$ and IL-6 [5, 6]. However, in the recent years it was also suggested that alteration in gut microbiota composition followed by an impairment of intestinal wall integrity is additional factor escalating systemic microinflammation, at least in the obese [7]. Systemic microinflammation is an important link in the pathogenesis of insulin resistance and comorbidities related to obesity, such as hypertension, dyslipidemia, and type 2 diabetes [8, 9].

The discovery of zonula occludens toxin (Zot), a Vibrio cholera enterotoxin, and later its eukaryotic counterpart zonulin increased cognition of the mechanisms that regulate the intestinal paracellular pathway. Zonulin is a mediator
Table 1: The comparison of anthropometric and metabolic parameters in the study groups (median values and interquartile ranges).

| Parameter                        | Obese                  | Normal weight | Statistical significance |
|----------------------------------|------------------------|---------------|-------------------------|
| Age (years)                      | 53.5 (42.0–63.0)       | 42.5 (32.0–52.0) | P < 0.01                |
| BMI (kg/m²)                      | 35.4 (30.6–38.7)       | 23.7 (21.8–24.8) | P < 0.001               |
| Fat mass (kg)                    | 43.3 (36.2–50.2)       | 20.1 (17.6–24.7) | P < 0.001               |
| Fat (%)                          | 46.7 (40.9–49.9)       | 32.5 (28.4–40.0) | P < 0.001               |
| Total cholesterol (mg/dL)        | 183.0 (158–219)        | 195.0 (156–215)  | Ns                      |
| LDL-cholesterol (mg/dL)          | 134 (103–172)          | 117 (94–140)    | Ns                      |
| HDL-cholesterol (mg/dL)          | 46 (37–56)             | 58 (45–70)      | P < 0.001               |
| Triglycerides (mg/dL)            | 120 (92–156)           | 87 (66–109)     | P < 0.001               |
| Glucose (mmol/L)                 | 4.9 (4.4–5.5)          | 4.6 (4.3–4.8)   | P < 0.05                |
| Insulin (µU/mL)                  | 11.1 (8.0–13.8)        | 7.4 (5.3–9.7)   | P < 0.01                |
| HOMA-IR                          | 2.2 (1.7–3.2)          | 1.5 (1.1–1.9)   | P < 0.01                |
| Hemoglobin A1C (%)               | 5.3 (4.8–5.6)          | 5.0 (4.8–5.3)   | P < 0.05                |

Diet

| Parameter                        | Obese                  | Normal weight | Statistical significance |
|----------------------------------|------------------------|---------------|-------------------------|
| Energy intake (kcal/day)         | 2550 (2043–2923)       | 1625 (1488–1813) | P < 0.001               |
| Protein (%)                      | 14.0 (12.3–16.3)       | 16.3 (13.0–17.7) | P < 0.001               |
| Fat (%)                          | 43.0 (38.3–46)         | 37.7 (31.7–41.0) | P < 0.05                |
| Carbohydrates (%)                | 43.7 (39.7–477)        | 46.7 (41.0–52.3) | P < 0.01                |
| Fiber (g/1000 kcal)              | 8.0 (6.5–9.7)          | 6.1 (2.0–10.8)  | Ns                      |

Gut microbiota

| Parameter                        | Obese                  | Normal weight | Statistical significance |
|----------------------------------|------------------------|---------------|-------------------------|
| The total bacterial count (CFU/µL) | 3084 (2230–3571)     | 2725 (2422–2989) | Ns                      |
| Bacteroides (CFU/µL)             | 800 (500–1000)         | 600 (500–812)  | Ns                      |
| Firmicutes spp. (CFU/µL)         | 532 (306–910)          | 716 (405–1000) | Ns                      |
| The rate of Bacteroides/Firmicutes spp. | 1.1 (0.8–1.9)   | 0.7 (0.5–1.7)  | Ns                      |


known to regulate intestinal permeability by modulating intracellular tight junctions (TJs) [10, II]. Human zonulin (47-kDa protein) increases intestinal permeability in small intestine and participates in the development of intestinal innate immunity [III], encoded by haptoglobin 2 gene [12]. Circulating zonulin is considered as a potential marker of intestinal permeability [13]. The results of recently published study revealed higher circulating zonulin level in obese than in nonobese subjects and in subjects with glucose intolerance in comparison to group with normal glucose tolerance. Moreover, the positive correlation between serum zonulin level and BMI, WHR, fasting insulin, and triglycerides levels as well as plasma IL-6 concentration but negative with HDL-cholesterol level and insulin sensitivity was found [14]. Therefore, we hypothesized that circulating zonulin levels may be a link between alteration in the gut microbiota composition and systemic microinflammation in obese subjects.

The aim of the study is the assessment of plasma zonulin, haptoglobin, and proinflammatory cytokines (TNF-α and IL-6) levels in relation to composition of gut microbiota in obese and normal weight subjects.

2. Materials and Methods

Eighty subjects without concomitant diseases, 50 obese (39 women and 11 men) and 30 normal weight (24 women and 6 men), were enrolled. Subjects with acute or chronic diseases, any drug use, including antibiotics and oral contraceptive agents, body mass change exceeding more than 3 kg during preceding 6 months, cigarette smoking, drinking more than 3 drinks per week, endocrine disorders, that is hyper- and hypothyroidisms, Cushing’s syndrome, and polycystic ovary syndrome were excluded. The characteristics of study group are presented in Table 1.

The study protocol was approved by the Bioethics Committee of Medical University of Silesia (KNW/0022/KBI/41/10). Informed consent was obtained from each study participant.

Anthropometric parameters (body mass, height, and waist circumference) were measured in the morning between 8 and 9 after 16-hour overnight fast. BMI was calculated according to standard formula. Body composition was measured using the bioimpedance method (Bodystat 1500, Douglas, Isle of Man).

Dietary energy and macronutrients intake were assessed on the basis of a three-day food diary completed by each study subject. The computer database of foods from the National Food and Nutrition Institute (Diet 4.0, Polish Food Tables 2005) was used to calculate the energy and micronutrient dietary intake.

2.1. Biochemical Measurements. The 8 mL samples of venous blood were collected in the morning between 8 and 9 a.m.,
after overnight fast (16 h), according to the recommendations of the kit manufacturers. Serum and plasma samples were stored at −80°C. Serum glucose, total cholesterol, LDL, and HDL cholesterol as well as triglycerides were estimated by colorimetric methods using a commercially available test kit (Roche Diagnostics GmbH, Mannheim, Germany). Serum insulin concentration was determined by electrochemiluminescence method (Cobas e411, Roche Diagnostics GmbH, Mannheim, Germany). Serum insulin resistance was diagnosed with HOMA-IR value above 2.49.

The plasma concentrations of TNF-α, sTNFRs, and IL-6 were measured using a commercially available highly sensitive ELISA kits (R&D Systems, MN, U.S.A). The sensitivity of the TNF-α assay was less than 0.1 pg/mL. Mean intra-assay coefficient of variance was less than 4.3% and mean inter-assay coefficient of variance was 7.3%. The sensitivities of the sTNFRI and sTNFR2 assays were typically less than 0.77 pg/mL and 0.6 pg/mL, respectively. Mean intra-assay coefficients of variance were <3.6% and 2.6%, respectively, and mean inter-assay coefficients of variance were 3.7% and 3.5%, respectively. The sensitivity of the IL-6 assay was less than 0.04 pg/mL. Mean intra-assay coefficient of variance was less than 7.8% and mean inter-assay coefficient of variance was 7.2%.

Plasma zonulin concentrations were measured by ELISA (Immundiagnostik AG, Bensheim, Germany). The sensitivity of the assay was less than 0.01 ng/mL. Mean intra- and inter-assay coefficients of variance were 5% and 8.5%, respectively.

The K5600 ELISA kit used for zonulin measurement detects only the active form of zonulin.

Plasma haptoglobin concentration was assessed by ELISA (AssayPro, Saint Charles, MO, U.S.A). The sensitivity of the assay was less than 0.07 μg/mL. Intra-assay and inter-assay coefficients of variation were 4.9% and 7.5%, respectively.

2.2. Analysis of Fecal Microflora. All 80 fecal samples were obtained from study subjects without use of laxatives, preventing contamination with urine. The samples were collected in a sterile disposable container without fluid and delivered to the laboratory within two hours on the day of blood sample collection and processed according to the scheme presented in Figure 1. Each fecal sample was diluted (1:100) in PBS, cultured using the appropriate media (numbers 1–9) in aerobic (numbers 1–5) and anaerobic (numbers 6–9) conditions, respectively:

(1) CBA: Columbia blood agar (bioMerieux, Marcy L’Etoile, France),
(2) MC: MacConkey agar (Becton, Dickinson and Company, France),
(3) Ch: CHAPMAN agar with mannitol (Becton, Dickinson and Company, USA),
(4) Sab: Sabouraud agar (bioMerieux, Marcy L’Etoile, France),
(5) DCO: D-Coccosel agar (bioMerieux, Marcy L’Etoile, France),
(6) MRS: MRS agar (Becton, Dickinson and Company, France),
(7) RC: Reinforced Clostridial agar (Oxiod, UK),
(8) ChAPMAN mannitol agar (bioMerieux, Marcy L’Etoile, France),
(9) Sabouraud agar (bioMerieux, Marcy L’Etoile, France),
(10) D-Coccosel agar (bioMerieux, Marcy L’Etoile, France),
(11) MRS agar (Becton, Dickinson and Company, France),
(12) Reinforced Clostridial agar (Oxiod, UK),
(13) Columbia blood agar (bioMerieux, Marcy L’Etoile, France),
(14) MacConkey agar (Becton, Dickinson and Company, France),
(15) CHAPMAN mannitol agar with mannitol (Becton, Dickinson and Company, USA),
(16) Sabouraud agar (bioMerieux, Marcy L’Etoile, France),
(17) D-Coccosel agar (bioMerieux, Marcy L’Etoile, France),
(18) MRS agar (Becton, Dickinson and Company, France),
(19) Reinforced Clostridial agar (Oxiod, UK),
(20) Columbia blood agar (bioMerieux, Marcy L’Etoile, France),
(21) MacConkey agar (Becton, Dickinson and Company, France),
(22) CHAPMAN mannitol agar with mannitol (Becton, Dickinson and Company, USA),
(23) Sabouraud agar (bioMerieux, Marcy L’Etoile, France),
(24) D-Coccosel agar (bioMerieux, Marcy L’Etoile, France),
(25) MRS agar (Becton, Dickinson and Company, France),
(26) Reinforced Clostridial agar (Oxiod, UK).

**Figure 1:** Fecal samples processing scheme.
Table 2: The comparison of inflammation parameters in the study groups (median values with interquartile ranges).

| Parameter | Obese (N = 50) | Normal weight (N = 30) | Statistical significance |
|-----------|----------------|------------------------|-------------------------|
| TNF-α (pg/mL) | 1.5 (1.4–1.8) | 1.3 (0.9–1.6) | P < 0.01 |
| sTNFRI (pg/mL) | 1772 (1447–2079) | 1049 (909–1486) | P < 0.001 |
| sTNFR2 (pg/mL) | 3414 (2717–3805) | 2877 (2303–3244) | P < 0.01 |
| IL-6 (pg/mL) | 1.9 (1.8–2.5) | 1.0 (0.8–2.1) | P < 0.001 |
| Haptoglobin (μg/mL) | 1.5 (1.2–2.0) | 1.3 (1.0–1.7) | Ns |
| Zonulin (ng/mL) | 8.2 (7.1–8.4) | 5.4 (4.8–6.8) | P < 0.001 |

Figure 2: The comparison of mean zonulin concentrations in study groups.

2.3. Statistical Analysis. Statistical analysis was performed using the STATISTICA 10.0 PL software (StatSoft Poland, Cracow, Poland). The results are presented as median values with interquartile ranges. The Chi-square test was used for comparison of the frequency of qualitative variables in studied groups and Mann-Whitney U tests were used for comparison of quantitative variables between groups. The univariate correlation coefficients were calculated according to Spearman. Five models of multiple regression analyses for zonulin level and alternative sets of potentially explanatory variables were used: the total bacterial count and total Bacteroides and Firmicutes counts, energy intake and macronutrients content, and parameters of carbohydrate and lipid metabolism, as well as inflammation parameters. The results were considered as statistically significant with a P value of less than 0.05.

3. Results

3.1. Characteristics of Study Groups. As a consequence of the inclusion criteria, body mass, BMI, and the body fat mass and percentage were higher in the obese than in normal weight group (Table 1). The obese group were older by 9 years in average than normal weight group.

Serum glucose, insulin, and triglycerides concentrations and HOMA-IR and HbA1c values were higher, while serum HDL-cholesterol level was significantly lower in obese group (Table 1).

The mean daily energy consumption and the percentages of fat content in the diet were higher, while the percentage of carbohydrate and protein were lower in obese group than in normal weight group. The fiber consumption per daily energy intake was similar in both groups (Table 1).

The total bacterial as well as Bacteroides and Firmicutes counts and the rate of Bacteroides to Firmicutes spp. were similar in both study groups (Table 1). Significantly higher plasma TNF-α, sTNFRI, sTNFR2, IL-6, and zonulin levels were observed in the obese group (Table 2, Figure 2), while plasma haptoglobin level did not differ statistically in both study groups.
and macronutrients dietary intake, HOMA-IR value, intestinal bacterial counts, mediators of inflammation, glucose, and lipid profile (Table 3). In subgroups with sTNFR1 ≥ 1510 pg/mL, haptoglobin ≥ 1.42 μg/mL, and daily energy intake ≥ 2095 kcal/d, significantly higher plasma zonulin levels were found.

3.3. Correlation Analyses. The correlation coefficients were calculated for all study subjects. Plasma zonulin level correlated positively with age (R = 0.43, P < 0.001), body mass (R = 0.30, P < 0.01), BMI (R = 0.33, P < 0.01) (Figure 3), fat mass and percentage (R = 0.31, P < 0.01 and R = 0.23, P < 0.05, resp.). Moreover, positive correlation between plasma zonulin level and total bacterial count (R = 0.26, P < 0.05) as well as sTNFRI (R = 0.34, P < 0.01) and haptoglobin levels (R = 0.36, P < 0.01) (Figure 3) was shown. Furthermore, plasma zonulin was proportional to daily energy intake (R = 0.27, P < 0.05) and inversely proportional to protein percentage dietary intake (R = −0.23, P < 0.05). Additionally, serum glucose concentration correlated positively with zonulin level (Table 4).

Plasma haptoglobin correlated significantly only with age (R = 0.25, P < 0.05), fat mass and percentage (R = 0.26, P < 0.05 and R = 0.34, P < 0.01, resp.).

Plasma sTNFRI level also correlated significantly with the total bacterial count (R = 0.33, P < 0.01). Moreover, both plasma sTNFR1 and sTNFR2 as well as IL-6 levels were proportional to daily energy intake (r = 0.30, P < 0.01; r = 0.27, P < 0.05; and r = 0.31, P < 0.01, resp.).

Neither Bacteroides and Firmicutes counts nor percent- ages correlated significantly with levels of zonulin and other inflammatory markers assessed.

Insulin levels and HOMA-IR correlated positively with circulating sTNFRs and IL-6 but not with TNF-α levels. Moreover, there was an inverse relation between concentrations of HDL-cholesterol and plasma TNF-α, sTNFR1, and IL-6 but not zonulin and sTNFR2 levels (Table 4).

3.4. Multiple Regression Analyses. In multiple regression model including the composition of gut microbiota as an independent variable, zonulin level was only related to total bacteria count (β = 0.33 ± 0.13) but not to the count of Bacteroides or Firmicutes. Both BMI (β = 0.26 ± 0.10) and age (β = 0.31 ± 0.06) were in addition to total bacterial count (β = 0.23 ± 0.10) explanatory variables for circulating zonulin concentration.

In the model including dietary variables, as independent variables, zonulin level was related to fat percentage in diet (β = 0.23 ± 0.11) and fiber intake in relation to daily energy consumption (β = 0.32 ± 0.12).
In the model including parameters of carbohydrates metabolism, zonulin variability was explained only by glucose levels ($\beta = 0.38 \pm 0.12$). Zonulin variability was not related to lipid metabolism parameters.

4. Discussion

In accordance with recently published study [14], we observed higher circulating zonulin level, a known mediator of intestinal permeability, modulating intracellular tight junctions (TJs) [9, 10] in obese subjects. Additionally, we observed that plasma zonulin, but not haptoglobin level, was proportional to total bacteria count.

Recently a lot of interest has raised the role of gut microbiota in the pathogenesis of obesity and its concomitant diseases [15]. Bacteria colonizing the gut are the source of shell fragment G(−) bacteria, lipopolysaccharide (LPS), an inducer of low-grade chronic inflammation. Increased concentrations of LPS in the gut and in the plasma were observed in obese, diabetic subjects consumed a rich-fat diet [16, 17]. LPS stimulates secretion of proinflammatory cytokines, such as TNF-\(\alpha\), IL-1, and IL-6 by immune cells [15].

It should be emphasized that in our study neither Bacteroides and Firmicutes spp. counts nor their percentages were associated with the levels of circulating zonulin and other assessed inflammatory markers. It is suggested that for the induction of low-grade inflammation in the obese, total bacteria count is more important than the gut microbiota composition. Abundant gut microbiota and its composition in the obese depend on the energy consumption and diet composition [18].

The higher daily energy consumption in the obese is another explanation for systemic microinflammation expressed by increased circulating zonulin levels. We observed that zonulin level was associated with daily energy consumption in a univariate analysis only with diet composition (fiber intake in relation to daily energy consumption and fat percentage in diet) in a multiple regression analysis; thus circulating plasma zonulin concentration is mostly associated with higher fat consumption causing the increased daily energy intake. It seems that fat consumption may stimulate bacteria growth, while fiber is the substrate for fermentation.

### Table 3: The comparison of zonulin concentrations in groups according to different parameters (mean and 95% confidential interval).

| Gender       | Zonulin (ng/mL) | P   |
|--------------|----------------|-----|
| Females; n = 54 | 7.1 (6.4–7.7)  |     |
| Males; n = 26  | 6.7 (5.5–8.0)  | Ns  |

| Diet         | Zonulin (ng/mL) | P   |
|--------------|----------------|-----|
| Total energy intake < 2093 kcal/d; n = 40 | 6.3 (5.5–7.0) |     |
| Total energy intake ≥ 2095 kcal/d; n = 40 | 7.8 (7.0–8.6) | P < 0.01 |
| Fat < 41%; n = 41 | 7.2 (6.3–8.1)  |     |
| Fat ≥ 41%; n = 39 | 6.8 (6.1–7.6)  | Ns  |

| Lipid profile | Zonulin (ng/mL) | P   |
|---------------|----------------|-----|
| Total cholesterol < 200 mg/dL; n = 50 | 6.8 (6.1–7.5) |     |
| HDL < 40 (M) and <50 mg/dL (F); n = 37 | 7.2 (6.3–8.1) |     |
| HDL ≥ 40 (M) and ≥50 mg/dL (F); n = 43 | 6.7 (5.9–7.5) |     |
| LDL < 135 mg/dL; n = 49 | 6.4 (5.6–7.1) |     |
| LDL ≥ 135 mg/dL; n = 31 | 7.4 (6.5–8.2) | Ns  |

| Insulin resistance | Zonulin (ng/mL) | P   |
|--------------------|----------------|-----|
| Insulin level > 15.4 \(\mu\) U/mL; n = 21 | 7.4 (6.3–8.4) |     |
| Insulin level ≤ 15 \(\mu\) U/mL; n = 59 | 6.6 (5.8–7.5) | Ns  |
| HOMA ≥ 2.49; n = 28 | 7.6 (6.2–9.0) |     |
| HOMA < 2.49; n = 52 | 6.5 (5.7–7.3) | Ns  |
| Glucose ≥ 100 mg/dL; n = 12 | 8.2 (5.9–9.7) |     |
| Glucose < 100 mg/dL; n = 68 | 7.0 (4.7–8.9) | Ns  |

| Bacterial content | Zonulin (ng/mL) | P   |
|-------------------|----------------|-----|
| Total bacterial count < 2829; n = 40 | 6.4 (5.6–7.3) |     |
| Total bacterial count ≥ 2829; n = 40 | 7.5 (6.6–8.4) | Ns  |
| Bacteroides count < 800; n = 39 | 6.6 (5.7–7.5) |     |
| Bacteroides count ≥ 800; n = 41 | 7.4 (6.8–8.1) | Ns  |
| Firmicutes count < 585; n = 39 | 6.9 (6.7–7.7) |     |
| Firmicutes count ≥ 585; n = 41 | 7.1 (6.2–8.0) | Ns  |
| Bacteroides < 26%; n = 38 | 7.1 (6.1–8.0) |     |
| Bacteroides ≥ 26%; n = 42 | 6.7 (5.9–7.6) | Ns  |
| Firmicutes < 22%; n = 40 | 7.3 (6.4–8.1) |     |
| Firmicutes ≥ 22%; n = 40 | 6.6 (5.8–7.5) | Ns  |
| Firmicutes/Bacteroides index < 1.1; n = 32 | 6.9 (5.9–7.8) |     |
| Firmicutes/Bacteroides index ≥ 1.1; n = 48 | 7.1 (6.4–7.9) | Ns  |

### Table 3: Continued.

| Inflammatory markers | Zonulin (ng/mL) | P   |
|----------------------|----------------|-----|
| TNF-\(\alpha\) < 1.45 pg/mL; n = 38 | 7.2 (6.2–8.1) |     |
| TNF-\(\alpha\) ≥ 1.45 pg/mL; n = 42 | 6.7 (5.8–7.6) | Ns  |
| sTNFR1 < 150 pg/mL; n = 39 | 6.2 (5.2–7.2) |     |
| sTNFR1 ≥ 150 pg/mL; n = 41 | 7.6 (6.8–8.3) | P < 0.01 |
| sTNFR2 < 3103 pg/mL; n = 40 | 6.5 (5.6–7.3) |     |
| sTNFR2 ≥ 3103 pg/mL; n = 40 | 7.3 (6.4–8.3) | Ns  |
| IL-6 < 1.6 pg/mL; n = 41 | 6.8 (5.9–7.7) |     |
| IL-6 ≥ 1.6 pg/mL; n = 39 | 7.0 (6.1–8.0) | Ns  |
| Haptoglobin < 1.42 \(\mu\)g/mL; n = 39 | 6.1 (5.3–6.9) |     |
| Haptoglobin ≥ 1.42 \(\mu\)g/mL; n = 41 | 7.8 (6.9–8.8) | P < 0.01 |
Table 4: The univariate correlations of study parameters in the whole group of subjects.

|                  | Zonulin | TNF-α | sTNFR1 | sTNFR2 | IL-6  |
|------------------|---------|-------|--------|--------|-------|
| Age              | \( R = 0.43 \)\( ^* \) | \( R = 0.21 \) | \( R = 0.25 \)\( ^* \) | \( R = 0.27 \)\( ^* \) | \( R = 0.25 \)\( ^* \) |
| Body mass        | \( R = 0.34 \)\( ^* * \) | \( R = 0.29 \)\( ^* \) | \( R = 0.6 \)\( ^< \) | \( R = 0.3 \) | \( R = 0.51 \)\( ^< \) |
| BMI              | \( R = 0.41 \)\( ^< \) | \( R = 0.30 \)\( ^< \) | \( R = 0.67 \)\( ^< \) | \( R = 0.35 \)\( ^< \) | \( R = 0.58 \)\( ^< \) |
| Fat mass         | \( R = 0.42 \)\( ^< \) | \( R = 0.29 \)\( ^< \) | \( R = 0.61 \)\( ^< \) | \( R = 0.33 \)\( ^< \) | \( R = 0.57 \)\( ^< \) |
| Fat percentage   | \( R = 0.40 \)\( ^< \) | \( R = 0.22 \) | \( R = 0.48 \)\( ^< \) | \( R = 0.29 \)\( ^< \) | \( R = -0.52 \)\( ^< \) |
| Diet             |         |       |        |        |       |
| Total energy intake | \( R = 0.27 \)\( ^* \) | \( R = 0.04 \) | \( R = 0.30 \)\( ^* \)\( ^* \) | \( R = 0.27 \)\( ^* \) | \( R = 0.31 \)\( ^* \)\( ^* \) |
| Fat              | \( R = 0.15 \) | \( R = 0.16 \) | \( R = 0.15 \) | \( R = 0.04 \) | \( R = 0.29 \)\( ^* \) |
| Carbohydrates    | \( R = -0.01 \) | \( R = -0.15 \) | \( R = -0.02 \) | \( R = 0.04 \) | \( R = -0.19 \) |
| Protein          | \( R = -0.23 \)\( ^* \) | \( R = 0.05 \) | \( R = -0.02 \) | \( R = -0.12 \) | \( R = -0.11 \) |
| Fiber            | \( R = 0.08 \) | \( R = 0.06 \) | \( R = 0.14 \) | \( R = 0.07 \) | \( R = -0.01 \) |
| Biochemical parameters |       |       |        |        |       |
| Glucose          | \( R = 0.18 \)\( ^* \) | \( R = 0.01 \) | \( R = 0.08 \) | \( R = 0.11 \) | \( R = 0.05 \) |
| Insulin          | \( R = 0.12 \) | \( R = 0.13 \) | \( R = 0.26 \)\( ^* \) | \( R = 0.27 \)\( ^* \) | \( R = 0.41 \)\( ^< \) |
| HOMA-IR          | \( R = 0.15 \) | \( R = 0.17 \) | \( R = 0.25 \)\( ^* \) | \( R = 0.26 \)\( ^* \) | \( R = 0.37 \)\( ^* * \) |
| HgbAIC           | \( R = 0.08 \) | \( R = 0.12 \) | \( R = 0.01 \) | \( R = 0.07 \) | \( R = 0.20 \) |
| Total cholesterol| \( R = 0.09 \) | \( R = 0.05 \) | \( R = -0.06 \) | \( R = -0.12 \) | \( R = -0.09 \) |
| HDL-cholesterol  | \( R = -0.07 \) | \( R = -0.32 \)\( ^* * \) | \( R = -0.33 \)\( ^* * \) | \( R = -0.21 \) | \( R = -0.38 \)\( ^* * \) |
| LDL-cholesterol  | \( R = 0.21 \) | \( R = 0.09 \) | \( R = 0.01 \) | \( R = -0.09 \) | \( R = 0.02 \) |
| Triglycerides    | \( R = 0.19 \) | \( R = 0.12 \) | \( R = 0.22 \) | \( R = 0.13 \) | \( R = 0.28 \)\( ^* \) |
| TNF-α            | \( R = -0.01 \) | — | \( R = 0.25 \)\( ^* \) | \( R = 0.13 \) | \( R = 0.37 \)\( ^* * \) |
| sTNFR1           | \( R = 0.34 \)\( ^* * \) | \( R = 0.25 \)\( ^* \) | — | \( R = 0.61 \)\( ^< \) | \( R = 0.34 \)\( ^* * \) |
| sTNFR2           | \( R = 0.16 \) | \( R = 0.13 \) | \( R = 0.61 \)\( ^< \) | — | \( R = 0.30 \)\( ^* * \) |
| IL-6             | \( R = 0.04 \) | \( R = 0.33 \)\( ^* * \) | \( R = 0.37 \)\( ^* * \) | \( R = 0.30 \)\( ^* * \) | — |

*\( P < 0.05 \); **\( P < 0.01 \); ^\( P < 0.001 \).

in the colon. The process of gut microbiota-dependent fermentation of indigestible polysaccharides in the colon is the source of gaining extra energy from food. The fermentation product, propionic acid, is a substrate for the gluconeogenesis and lipogenesis [19].

Moreno-Navarrete et al. [14] have shown higher circulating zonulin level in subjects with impaired than normal glucose tolerance irrespective of body mass. Thus, zonulin seems to be one of factors contributing to insulin resistance development; however, the association disappeared after adding plasma IL-6 level to the multiple regression analysis model [14]. We did not observe association between zonulin level and insulin resistance (scored as HOMA-IR above 2.49). This difference may be the result of remarkably lower percentage of insulin-resistant subjects in our study group. However, in accordance with the results obtained by Moreno-Navarrete et al. [14], relationship between circulating glucose and zonulin levels was shown in our study.

In a similar way we failed to prove the association between serum lipid and circulating zonulin levels, previously described by Moreno-Navarrete et al. [14]. It should be emphasized that increased total cholesterol, LDL-cholesterol, and triglycerides as well as decreased HDL-cholesterol levels in our study group were less frequent than in the cited study.

We observed positive association between circulating zonulin and sTNFR1 levels. Additionally, plasma zonulin level was higher in the subgroups with sTNFR1 concentration above 1510 pg/mL (median value). The sTNFR1 is a sensitive marker of low-grade inflammation in the obese [20]. Thus, these results confirm that circulating zonulin is an inflammatory marker, as its precursor, haptoglobin (Hp) [12], a liver acute-phase response protein. The expression of Hp in hepatocytes is increased by a number of proinflammatory cytokines including IL-1, IL-6, and TNF-α [21, 22]. Our results are extending these findings, demonstrating the proportional relation between circulating levels of haptoglobin...
and zonulin. However, as both proteins are the products of the same gene, a stronger than shown \((R = 0.36)\) correlation might be expected. This may suggest the different and perhaps organ-specific secretion of these proteins. Whether this hypothesis is true remains to be verified. Chiellini et al. showed that Hp expression is upregulated in the white adipose tissue (WAT) in the obese rodents depending on the TNF-\(\alpha\) pathway [23]. It was also observed that the factor stimulating haptoglobin mRNA expression in adipose tissue to the levels comparable to those in liver is LPS. However, this stimulation is secondary to the enhanced release of proinflammatory cytokines such as IL-1, IL-6 and, TNF-\(\alpha\) [22].

The results of numerous studies revealed that circulating Hp level is proportional to BMI and components of metabolic syndrome [23–26]. Contrary to Moreno-Navarrete et al. [14], we showed the positive correlation between BMI and zonulin level. These data suggest that zonulin, the product of the different splicing of Hp2 gene exons [20], is a new potential marker of systemic microinflammation associated with obesity and is more sensitive than haptoglobin [23, 27, 28]. However, the correlation between total bacteria count in feces and circulating zonulin in our study suggests that it is rather the maker of gut mucosa inflammation in the obese than in the visceral adipose tissue. Our hypothesis may be supported by some recent findings. It was shown that probiotics administration in patients diagnosed with colorectal carcinoma reduces postoperative septicemia and is associated with reduced circulating zonulin level [29]. Additionally, increased zonulin levels were found in septic patients, potentially reflecting increased intestinal permeability in sepsis [30]. As already mentioned, abundant growth of gut microbiota is the consequence of high energy consumption by the obese related to high dietary fat intake. Thus increased intestinal permeability in the obese may be the effect of long-lasting inappropriate nutritional habits. Further studies are necessary to confirm our hypothesis.

The limitation of our study, beyond the size of the study groups, is the methodology of microbiome analysis and the lack of endotoxin assessment as well as the assessment of energy and macronutrients dietary intake based on a three-day food diary only.

5. Conclusions

Gut microbiota-related systemic microinflammation in the obese is reflected by circulating zonulin level, a potential marker of interstitial permeability.

Conflict of Interests

The authors have nothing to disclose and all authors declare no conflict of interests.

Acknowledgment

The study was supported by the grant from Medical University of Silesia.

References

[1] F. Bäckhed, H. Ding, T. Wang et al., “The gut microbiota as an environmental factor that regulates fat storage,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 44, pp. 15718–15723, 2004.

[2] B. Zahorska-Markiewicz, J. Janowska, M. Olszanecka-Glinianowicz, and A. Zurakowski, “Serum concentrations of TNF-\(\alpha\) and soluble TNF-\(\alpha\) receptors in obesity,” International Journal of Obesity, vol. 24, no. II, pp. 1392–1395, 2000.

[3] M. Olszanecka-Glinianowicz, B. Zahorska-Markiewicz, J. Janowska, and A. Zurakowski, “Serum concentrations of nitric oxide, tumor necrosis factor (TNF-\(\alpha\)) and TNF soluble receptors in women with overweight and obesity,” Metabolism, vol. 53, no. 10, pp. 1268–1273, 2004.

[4] M. Olszanecka-Glinianowicz, J. Chudek, P. Kocelak, A. Szromek, and B. Zahorska-Markiewicz, “Body fat changes and activity of tumor necrosis factor \(\alpha\) system-a 5-year follow-up study,” Metabolism, vol. 60, no. 4, pp. 531–536, 2011.

[5] G. Winkler, S. Kiss, L. Keszthelyi et al., “Expression of tumor necrosis factor (TNF-\(\alpha\)) protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNF-\(\alpha\), soluble serum TNF-receptor-2 concentrations and C-peptide level,” European Journal of Endocrinology, vol. 149, no. 2, pp. 129–135, 2003.

[6] S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante Jr., “Obesity is associated with macrophage accumulation in adipose tissue,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1796–1808, 2003.

[7] M. C. Arrieta, L. Bistritz, and J. B. Meddings, “Alterations in intestinal permeability,” Gut, vol. 55, no. 10, pp. 1512–1520, 2006.

[8] G. Reaven, F. Abbasi, and T. McLaughlin, “Obesity, insulin resistance, and cardiovascular disease,” Recent Progress in Hormone Research, vol. 59, pp. 207–223, 2004.

[9] M. Olszanecka-Glinianowicz and B. Zahorska-Markiewicz, “Obesity as inflammatory disease,” Postepy Higieny i Medycyny Doswiadczalnej, vol. 62, pp. 249–257, 2008.

[10] A. Fasano, “Regulation of intercellular tight junctions by zonula occludens toxin and its eukaryotic analogue zonulin,” Annals of the New York Academy of Sciences, vol. 915, pp. 214–222, 2000.

[11] W. Wang, S. Uzzau, S. E. Goldblum, and A. Fasano, “Human zonulin, a potential modulator of intestinal tight junctions,” Journal of Cell Science, vol. 113, no. 24, pp. 4435–4440, 2000.

[12] A. Tripathi, K. M. Lammers, S. Goldblum et al., “Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 39, pp. 16799–16804, 2009.

[13] E. Smeculov, E. Sugai, S. Niveloni et al., “Permeability, zonulin production, and enteropathy in dermatitis herpetiformis,” Clinical Gastroenterology and Hepatology, vol. 3, no. 4, pp. 335–341, 2005.

[14] J. Moreno-Navarrete, M. Sabater, F. Ortega, W. Ricart, and J. Fernandez-Real, “Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance,” PLoS One, vol. 7, no. 5, Article ID e37160, 2012.

[15] P. D. Cani, A. M. Neyrinck, F. Fava et al., “Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia,” Diabetologia, vol. 50, no. 11, pp. 2374–2383, 2007.
[16] J. Amar, R. Burcelin, J. B. Ruidavets et al., “Energy intake is associated with endotoxemia in apparently healthy men,” *American Journal of Clinical Nutrition*, vol. 87, no. 5, pp. 1219–1223, 2008.

[17] S. J. Creely, P. G. McTernan, C. M. Kusminski et al., “Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes,” *American Journal of Physiology*, vol. 292, no. 3, pp. E740–E747, 2007.

[18] J.-P. Furet, L.-C. Kong, J. Tap et al., “Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers,” *Diabetes*, vol. 59, no. 12, pp. 3049–3057, 2010.

[19] T. M. S. Wolever, P. Spadafora, and H. Eshuis, “Interaction between colonic acetate and propionate in humans,” *American Journal of Clinical Nutrition*, vol. 53, no. 3, pp. 681–687, 1991.

[20] A. Diez-Ruiz, G. P. Tilz, R. Zangerle, G. Baier-Bitterlich, H. Wachter, and D. Fuchs, “Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis,” *European Journal of Haematology*, vol. 54, no. 1, pp. 1–8, 1995.

[21] H. Baumann, K. K. Morella, and G. H. W. Wong, “TNF-α, IL-1β, and hepatocyte growth factor cooperative in stimulating specific acute phase plasma protein genes in rat hepatoma cells,” *Journal of Immunology*, vol. 151, no. 8, pp. 4248–4257, 1993.

[22] W. E. Friedrichs, A. L. Navarijo-Ashbaugh, B. H. Bowman, and F. Yang, “Expression and inflammatory regulation of haptoglobin gene in adipocytes,” *Biochemical and Biophysical Research Communications*, vol. 209, no. 1, pp. 250–256, 1995.

[23] C. Chiellini, F. Santini, A. Marsili et al., “Serum haptoglobin: a novel marker of adiposity in humans,” *Journal of Clinical Endocrinology and Metabolism*, vol. 89, no. 6, pp. 2678–2683, 2004.

[24] J. Hannerz, D. Greitz, and K. Ericson, “Is there a relationship between obesity and intracranial hypertension?” *International Journal of Obesity*, vol. 19, no. 4, pp. 240–244, 1995.

[25] N. G. Vallianou, A. A. Evangelopoulos, D. B. Panagiotakos et al., “Associations of acute-phase reactants with metabolic syndrome in middle-aged overweight or obese people,” *Medical Science Monitor*, vol. 16, no. 2, pp. CR56–CR60, 2010.

[26] P. Hämäläinen, J. Saltevo, H. Kautiainen, P. Mäntyselkä, and M. Vanhala, “Erythropoietin, ferritin, haptoglobin, hemoglobin and transferrin receptor in metabolic syndrome: a case control study,” *Cardiovascular Diabetology*, vol. 11, article 116, 2012.

[27] J. N. Fain, S. W. Bahouth, and A. K. Madan, “Haptoglobin release by human adipose tissue in primary culture,” *Journal of Lipid Research*, vol. 45, no. 3, pp. 536–542, 2004.

[28] I. K. Quaye, “Haptoglobin, inflammation and disease,” *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 102, no. 8, pp. 735–742, 2008.

[29] Z. H. Liu, M. J. Huang, X. W. Zhang et al., “The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after colorectal cancer surgery: a double-center and double-blind randomized clinical trial,” *American Journal of Clinical Nutrition*, vol. 97, no. 1, pp. 117–126, 2013.

[30] D. A. Klaus, M. C. Motal, U. Burger-Kleppe et al., “Increased plasma zonulin in patients with sepsis,” *Biochimia Medica*, vol. 23, no. 1, pp. 107–111, 2013.